Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 18, Number 7—July 2012
Research

Predicting Risk for Death from MRSA Bacteremia1

Mina PastagiaComments to Author , Lawrence C. Kleinman, Eliesel G. Lacerda de la Cruz, and Stephen G. Jenkins
Author affiliations: The Rockefeller University, New York, New York, USA (M. Pastagia); Mount Sinai School of Medicine, New York (L.C. Kleinman, E.G. Lacerda de la Cruz); and Weill Cornell School of Medicine, New York (S.G. Jenkins)

Main Article

Figure

Trend of methicillin-resistant Staphylococcus aureus (MRSA) infection strain types, New York, New York, USA, 2002–2007. VISA, vancomycin-intermediate S. aureus strains, hVISA, heteroresistant vancomycin-intermediate S. aureus strains.

Figure. . . Trend of methicillin-resistant Staphylococcus aureus (MRSA) infection strain types, New York, New York, USA, 2002–2007. VISA, vancomycin-intermediate S. aureus strains, hVISA, heteroresistant vancomycin-intermediate S. aureus strains.

Main Article

1Parts of the data in this article were presented at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy/Infectious Diseases Society of America Meeting, October 25–28, 2008, Washington, DC, USA; and the 19th European Congress of Clinical Microbiology and Infectious Diseases Meeting, May 16–19, 2009, Helsinki, Finland.

Page created: June 13, 2012
Page updated: June 13, 2012
Page reviewed: June 13, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external